CASP3 and neoplasm: Immunoblotting analysis of tumor lysates demonstrated that sorafenib treatment resulted in downregulation of PTEN, increased the activation of Akt and caspase-3, and upregulated LC3-II and Beclin-1 expression (Figure 7B).